| pubmed-article:1920342 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1920342 | lifeskim:mentions | umls-concept:C0034510 | lld:lifeskim |
| pubmed-article:1920342 | lifeskim:mentions | umls-concept:C0035094 | lld:lifeskim |
| pubmed-article:1920342 | lifeskim:mentions | umls-concept:C0003364 | lld:lifeskim |
| pubmed-article:1920342 | lifeskim:mentions | umls-concept:C0004147 | lld:lifeskim |
| pubmed-article:1920342 | lifeskim:mentions | umls-concept:C0022860 | lld:lifeskim |
| pubmed-article:1920342 | lifeskim:mentions | umls-concept:C1979963 | lld:lifeskim |
| pubmed-article:1920342 | lifeskim:mentions | umls-concept:C2003903 | lld:lifeskim |
| pubmed-article:1920342 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:1920342 | pubmed:dateCreated | 1991-11-4 | lld:pubmed |
| pubmed-article:1920342 | pubmed:abstractText | In this randomised double-blind parallel study, we compared the efficacy of labetalol and atenolol in a group of black (n = 33) and white (n = 34) hypertensives with uncomplicated essential hypertension after obtaining pretreatment renin profiles. After single-blind placebo (14-21 days), patients with standing diastolic BP between 105-119 mmHg were randomised to receive either labetalol (100-800 mg twice daily) or atenolol (50-100 mg once daily) to achieve a DBP less than 90 mmHg. Dosage titration occurred at weekly intervals for labetalol and biweekly for atenolol. The supine BP decrease with atenolol was -18/-14 vs. -6/-6 mmHg in whites vs. blacks respectively. With labetalol, it was -13/-12 in whites and -2/-7 mmHg in blacks. Standing BPs were: -19/-14 vs. -4/-5, whites vs. blacks with atenolol and -17/-17 vs. -19/-9 mmHg with labetalol. Neither labetalol nor atenolol was as effective in black compared with white hypertensives. The atenolol but not labetalol BP response was positively correlated with pretreatment renin values. | lld:pubmed |
| pubmed-article:1920342 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1920342 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1920342 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1920342 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1920342 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1920342 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1920342 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1920342 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:1920342 | pubmed:issn | 0950-9240 | lld:pubmed |
| pubmed-article:1920342 | pubmed:author | pubmed-author:TownsendRR | lld:pubmed |
| pubmed-article:1920342 | pubmed:author | pubmed-author:WrightJ TJTJr | lld:pubmed |
| pubmed-article:1920342 | pubmed:author | pubmed-author:DiPetteD JDJ | lld:pubmed |
| pubmed-article:1920342 | pubmed:author | pubmed-author:McKenneyJ MJM | lld:pubmed |
| pubmed-article:1920342 | pubmed:author | pubmed-author:GoodmanR PRP | lld:pubmed |
| pubmed-article:1920342 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1920342 | pubmed:volume | 5 | lld:pubmed |
| pubmed-article:1920342 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1920342 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1920342 | pubmed:pagination | 193-8 | lld:pubmed |
| pubmed-article:1920342 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:1920342 | pubmed:meshHeading | pubmed-meshheading:1920342-... | lld:pubmed |
| pubmed-article:1920342 | pubmed:meshHeading | pubmed-meshheading:1920342-... | lld:pubmed |
| pubmed-article:1920342 | pubmed:meshHeading | pubmed-meshheading:1920342-... | lld:pubmed |
| pubmed-article:1920342 | pubmed:meshHeading | pubmed-meshheading:1920342-... | lld:pubmed |
| pubmed-article:1920342 | pubmed:meshHeading | pubmed-meshheading:1920342-... | lld:pubmed |
| pubmed-article:1920342 | pubmed:meshHeading | pubmed-meshheading:1920342-... | lld:pubmed |
| pubmed-article:1920342 | pubmed:meshHeading | pubmed-meshheading:1920342-... | lld:pubmed |
| pubmed-article:1920342 | pubmed:meshHeading | pubmed-meshheading:1920342-... | lld:pubmed |
| pubmed-article:1920342 | pubmed:meshHeading | pubmed-meshheading:1920342-... | lld:pubmed |
| pubmed-article:1920342 | pubmed:meshHeading | pubmed-meshheading:1920342-... | lld:pubmed |
| pubmed-article:1920342 | pubmed:year | 1991 | lld:pubmed |
| pubmed-article:1920342 | pubmed:articleTitle | Renin profile, race, and antihypertensive efficacy with atenolol and labetalol. | lld:pubmed |
| pubmed-article:1920342 | pubmed:affiliation | Department of Medicine, Medical College of Virginia, Commonwealth University, Richmond. | lld:pubmed |
| pubmed-article:1920342 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1920342 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:1920342 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:1920342 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1920342 | lld:pubmed |
